Form 4 INSULET CORP For: Feb 17 Filed by: Kapples John W.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Insulet Corporation (PODD) PT Raised to $310 at BTIG
February 21, 2025 5:09 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $300.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q4 revenue of $597.5M (+17% y/y), beating the consensus estimate of $583M and above the top end of the ~$571-$586M guidance range. U.S. Omnipod revenue of $443.7M (+12.4% y/y) was ~$7.5M above consensus of $436.3M while International Omnipod revenue of $142.0 (+33.1% cc y/ y) was ~$2M higher than consensus. Drug Delivery sales were $11.8M (cons. $6.5M). Type 2 patients were >30% of new U.S. starts in Q4... More
